Evidence map›Paper›PMID 41965890›Full record

ArticleNature communications2026

Structural optimization of drug molecules with incrementally trained language models.

Tim Hörmann, Domenic Mayer, Max Lewandowski, Andrea Hunklinger, Thomas Wein, Daniel Merk

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tim HörmannDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID 0009-0006-4834-1738
Domenic MayerDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.
Max LewandowskiDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID 0009-0007-0497-6464
Andrea HunklingerDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID 0009-0008-6107-3859
Thomas WeinDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID 0009-0007-0256-7341
Daniel MerkDepartment of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany. daniel.merk@cup.lmu.de.ORCID 0000-0002-5359-8128

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101040355
6 · The paper itself

Abstract

Automating structural optimization of drug molecules for on-target potency by machine learning is an open challenge in chemistry. Here, we capitalize on the ability of chemical language models (CLMs) to learn from sequential data and design new molecules with desired properties. We establish a training strategy mimicking the learning trajectory of a drug discovery program. Incremental CLM fine-tuning with increasingly potent template molecules from a given structure-activity relationship (SAR) series successfully biases the model to design highly active analogues. Prospective application of this technique to ligand development enables the data-driven design of molecules exceeding known representatives of given bioactive chemotypes in potency without external scoring. Our results reveal an ability of CLMs to capture SAR patterns and long-range dependencies, and to exploit SAR knowledge in designing analogues with improved on-target activity de novo corroborating their applicability to structural optimization of drug molecules.

Indexed as

Drug DesignDrug DiscoveryMachine LearningLigandsPharmaceutical PreparationsStructure-Activity RelationshipLigandsPharmaceutical Preparations

Identifiers

PMID41965890
PMCPMC13076696

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.